Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$62.35 -3.6%	$35.44	$13.47 ▼ $72.98	$13.96B	1.84	19.46 million shs	35.64 million shs
RXRX Recursion Pharmaceuticals	$4.51 -1.1%	$5.34	$3.79 ▼ $12.36	$1.83B	0.99	13.18 million shs	14.04 million shs
SDGR Schrödinger	$23.56 -0.1%	$22.89	$16.60 ▼ $28.47	$1.72B	1.84	847,621 shs	550,395 shs
SMMT Summit Therapeutics	$24.01 +0.6%	$22.49	$2.10 ▼ $36.91	$17.83B	-0.94	3.88 million shs	1.60 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	0.00%	+23.84%	+136.58%	+6.68%	+342.32%
RXRX Recursion Pharmaceuticals	0.00%	+5.31%	-17.09%	-56.70%	-51.59%
SDGR Schrödinger	0.00%	-1.34%	-8.43%	-5.11%	+3.60%
SMMT Summit Therapeutics	0.00%	-0.38%	-3.01%	+11.70%	+437.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HIMS Hims & Hers Health	2.5772 of 5 stars	2.0	2.0	3.8	3.3	1.9
RXRX Recursion Pharmaceuticals	2.1564 of 5 stars	3.2	2.0	2.3	2.5	0.6
SDGR Schrödinger	2.4395 of 5 stars	3.5	1.0	3.3	2.5	0.6
SMMT Summit Therapeutics	2.9425 of 5 stars	4.5	1.0	4.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	2.08	Hold	$37.67	-39.59% Downside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.60	68.51% Upside
SDGR Schrödinger	3.00	Buy	$32.80	39.22% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	55.77% Upside

Current Analyst Ratings Breakdown

Latest SMMT, SDGR, RXRX, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	HIMS Hims & Hers Health	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/6/2025	HIMS Hims & Hers Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Mixed ➝ Mixed
5/6/2025	HIMS Hims & Hers Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$35.00 ➝ $39.00
5/6/2025	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell	$25.00 ➝ $30.00
5/6/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00 ➝ $61.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/29/2025	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$22.00 ➝ $26.00
4/29/2025	HIMS Hims & Hers Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $40.00
4/29/2025	HIMS Hims & Hers Health	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$44.00 ➝ $30.00

(Data available from 5/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$1.78B	7.82	N/A	N/A	$1.61 per share	38.73
RXRX Recursion Pharmaceuticals	$59.82M	30.65	N/A	N/A	$1.98 per share	2.28
SDGR Schrödinger	$230.49M	7.47	$0.63 per share	37.42	$7.60 per share	3.10
SMMT Summit Therapeutics	$700K	25,473.44	N/A	N/A	$0.11 per share	218.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	-$23.55M	$0.69	141.71	119.90	N/A	8.19%	10.97%	8.29%	8/4/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	N/A
SDGR Schrödinger	$40.72M	-$2.63	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	7/30/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)

Latest SMMT, SDGR, RXRX, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	SDGR Schrödinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/5/2025	Q1 2025	HIMS Hims & Hers Health	$0.12	$0.20	+$0.08	$0.20	$535.21 million	$586.01 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
2/28/2025	Q4 2024	RXRX Recursion Pharmaceuticals	-$0.36	-$0.53	-$0.17	-$0.53	$19.04 million	$4.60 million
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million
2/24/2025	Q4 2024	HIMS Hims & Hers Health	$0.09	$0.11	+$0.02	$0.11	$494.56 million	$481.14 million
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	N/A	2.14	1.82
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35
SDGR Schrödinger	N/A	4.11	4.11
SMMT Summit Therapeutics	N/A	8.31	8.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
RXRX Recursion Pharmaceuticals	89.06%
SDGR Schrödinger	79.05%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	13.71%
RXRX Recursion Pharmaceuticals	15.75%
SDGR Schrödinger	8.60%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	650	223.83 million	179.79 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable

SMMT, SDGR, RXRX, and HIMS Headlines

Recent News About These Companies

Deutsche Bank AG Has $8.55 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 19 at 3:57 AM | marketbeat.com

Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money

May 18 at 5:47 AM | fool.com

Jefferies Financial Group Inc. Acquires Shares of 45,001 Summit Therapeutics Inc. (NASDAQ:SMMT)

May 18 at 4:34 AM | marketbeat.com

Northern Trust Corp Has $15.55 Million Position in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 17 at 3:45 AM | marketbeat.com

Dimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)

May 16 at 3:19 AM | marketbeat.com

StockNews.com Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"

May 15, 2025 | marketbeat.com

BNP Paribas Financial Markets Invests $8.80 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 14, 2025 | marketbeat.com

Hsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 13, 2025 | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Average Target Price from Brokerages

May 13, 2025 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Raised to "Strong-Buy" at TD Cowen

May 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Buy" from Analysts

May 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Balyasny Asset Management L.P.

May 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain

May 9, 2025 | insidermonkey.com

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Sold by Bosun Asset Management LLC

May 9, 2025 | marketbeat.com

The Manufacturers Life Insurance Company Purchases 181,185 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)

May 8, 2025 | marketbeat.com

Can Summit Therapeutics Stock Double Your Money?

May 7, 2025 | finance.yahoo.com

Bayesian Capital Management LP Invests $1.20 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 7, 2025 | marketbeat.com

Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know

May 6, 2025 | zacks.com

Bellevue Group AG Has $3.04 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)

May 6, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Issues Quarterly Earnings Results

May 5, 2025 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Issues Earnings Results

May 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Hims & Hers Stock Soars on Novo Nordisk Collaboration
By Gabriel Osorio-Mazilli | April 30, 2025
View Hims & Hers Stock Soars on Novo Nordisk Collaboration
Hims & Hers Stock Rises on Fundamentals and Squeeze Potential
By Gabriel Osorio-Mazilli | May 6, 2025
View Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

SMMT, SDGR, RXRX, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

$62.35 -2.30 (-3.56%)

As of 03:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.51 -0.05 (-1.10%)

As of 04:00 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Schrödinger NASDAQ:SDGR

$23.56 -0.02 (-0.08%)

As of 04:00 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$24.01 +0.14 (+0.59%)

As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time